Why the study?
There are currently no feasible therapies to treat chronic fibrosis, making it important to explore aging processes and their role in inducing and exacerbating cardiac and pulmonary fibrosis.
Key points are not available for this paper at this time.
Design
Review
No takes yet. Share an insight, caveat, or question.
Supports exploration of senescence and inflammaging pathways for fibrosis therapies; hypothesis-generating, should not yet change practice.
Murtha et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: